Discontinued — last reported Q4 '23
Medtronic Stock-based compensation expense increased by 55.3% to $146.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 3.9%, from $152.00M to $146.00M. This is a positive signal — lower values indicate better performance for this metric.
A significant increase may indicate higher talent retention costs or aggressive equity incentive programs, which can dilute existing shareholders.
This metric captures the total non-cash expense recognized by the company for granting stock options, restricted stock u...
Common across all industries, particularly in large-cap companies with robust executive and employee incentive plans.
is_cat_stock_based_compensation_expense| Q3 '21 | Q4 '21 | Q1 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $107.00M | $92.00M | $49.00M | $41.00M | $55.00M | $48.00M | $73.00M | $35.00M | $49.00M | $87.00M | $103.00M | $152.00M | $93.00M | $94.00M | $146.00M |
| QoQ Change | — | -14.0% | -46.7% | -16.3% | +34.1% | -12.7% | +52.1% | -52.1% | +40.0% | +77.6% | +18.4% | +47.6% | -38.8% | +1.1% | +55.3% |
| YoY Change | — | — | — | -61.7% | -40.2% | -2.0% | +78.0% | -36.4% | +2.1% | +19.2% | +194.3% | +210.2% | +6.9% | -8.7% | -3.9% |